Integration of Transcriptome Profiling and Single-Cell Sequencing Analysis to Establish a CD8+ T Cell-Related Prognostic Model for Patients With NSCLC: From Assessment to Therapy.

Researchers have developed a new way to predict outcomes for patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer. The study focused on CD8+ T cells, which are immune cells that help fight cancer. By analyzing genetic information from multiple patient databases, scientists identified three specific biomarkers (CD52, CD69, and PLIN2) that can predict how well patients might respond to treatment. The research team created a risk model that divides patients into high-risk and low-risk groups based on these biomarkers. They found that patients in the low-risk group had stronger immune systems and were more likely to benefit from immunotherapy, while high-risk patients showed better responses to chemotherapy drugs like paclitaxel. This model could help doctors make more personalized treatment decisions for lung cancer patients. While this study doesn't directly involve acupuncture, many cancer patients use acupuncture as a complementary therapy to manage treatment side effects such as nausea, fatigue, and pain during chemotherapy or immunotherapy. Acupuncture may support overall wellbeing and quality of life during conventional cancer treatments. If you're considering acupuncture as part of your cancer care plan, discuss it with your oncology team and seek treatment from a licensed acupuncturist experienced in oncology support.

This study established a CD8+ T cell-related prognostic model for NSCLC patients using transcriptome profiling and single-cell sequencing. Researchers analyzed three datasets (TCGA-NSCLC, GSE183219, GSE42127) through Weighted Gene Co-expression Network Analysis and single-cell analysis. Using LASSO, univariate Cox regression, and multivariate Cox regression, they identified three biomarkers (CD52, CD69, PLIN2) and constructed a risk stratification model. The model demonstrated high accuracy in both training and validation cohorts. Patients were classified into high-risk and low-risk subgroups, with distinct immune landscapes: low-risk patients showed robust immune function favoring immunotherapy response, while high-risk patients exhibited immune dysfunction but greater sensitivity to paclitaxel chemotherapy. A clinical nomogram integrating the risk model with pathologic N and T stages showed superior prognostic prediction. This precision medicine approach enables personalized therapeutic strategies based on CD8+ T cell-related biomarkers for NSCLC management.